EUVIMEDEUVIMED entdecken
Crossref

Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis

Annette von Drygalski, Patrick, Manale Maksour, Michael Polson, Magdalena Lewandowska

NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026

DOI: 10.67209/aelg8729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Annette von Drygalski und 4 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abnormal uterine bleeding (AUB), a common gynecologic condition, can lead to iron deficiency anemia (IDA), which increases health complication risks and necessitates iron repletion. Intravenous (IV) iron products are a treatment modality for IDA; however, the amount of IV iron ordered varies among available products. These orders can differ from FDA-approved iron dosages; high-dose products—ferumoxytol (FXT), ferric carboxymaltose (FCM), and ferric derisomaltose (FDI)— have labeled dosing of at least 1000 mg, depending on the product. Furthermore, the impact of IV iron on reducing outpatient blood transfusions in women with AUB remains unknown.

Zitieren

APA

Drygalski, A. V., Patrick, Maksour, M., Polson, M., & Lewandowska, M. (2026). Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/aelg8729

Vancouver

Drygalski AV, Patrick, Maksour M, Polson M, Lewandowska M. Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/aelg8729

BibTeX
@article{Drygalski2026,
  author = {Drygalski, Annette von and Patrick and Maksour, Manale and Polson, Michael and Lewandowska, Magdalena},
  title = {Ferric derisomaltose achieves highest likelihood of ≥1000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  doi = {10.67209/aelg8729}
}
Kostenlos starten →